After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Celgene's bullish action is leaving behind a solid foundation from which the stock can mount a new bull leg.
The company's hepatitis C drug division is expected to see losses in the second half of the year.
Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.
Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.